Hidden throughout the human genome, like sleeper agents in the machinery of life, transposons make up roughly 40 to 50 percent of our DNA—yet scientists have only recently begun understanding how they shape disease. Now, researchers at Boston University Chobanian & Avedisian School of Medicine have discovered that these transposable elements, long thought to be silenced by the body's genetic guardians, are actively expressing in aging brains, and the way they're processed differs strikingly between Huntington's disease and Parkinson's disease.
The finding matters because it reframes how we think about normal brain aging and neurodegenerative decline. For most of our lives, our cells successfully keep transposons quiet through genome defense mechanisms—a kind of molecular lock-and-key system. But as we move from adolescence into adulthood, the brain naturally begins expressing more large RNA messages from these transposons, which cells then process into small RNAs measuring 18 to 32 nucleotides long. This shift appears to be a normal part of aging, yet it also seems to go awry in disease.
"Transposons are usually silenced by our cells' genome defense mechanisms, but we find that normal human brains developing from adolescence to adults will naturally express more large RNA messages from transposons, and then the brain cells will metabolize some proportion into small RNA through either active or passive mechanisms," explains Nelson Lau, Ph.D., associate professor of biochemistry and director of the BU Genome Science Institute. The research, published in Genome Research, examined how this processing becomes disrupted in two of the most common neurodegenerative disorders.
The team's investigation compared brain samples from patients with Huntington's disease and Parkinson's disease, using both publicly available datasets from the NIH BrainSpan Atlas consortium and unique datasets developed at Boston University. This dual approach gave the researchers something rare: matched sets of both large and small RNAs sequenced from the same human samples, allowing for precise tracking of how transposon RNA levels shift during disease progression. Their bioinformatics analysis revealed something striking: Huntington's disease primarily impacts transposon small RNA expression, while Parkinson's exerts a stronger impact on transposon large RNAs. The distinction suggests that these two diseases may arise from fundamentally different molecular origins.
This nuance could prove crucial. Huntington's disease has a known genetic cause—a mutation in the HTT gene—but Parkinson's disease remains genetically mysterious. By examining how each disease affects the expression and processing of transposon RNAs, researchers may uncover clues about what goes wrong at the molecular level in Parkinson's, where the origins remain obscure. "We asked if transposon RNA expression in these two disease states could shed some light on the molecular differences between these two disorders," Lau notes. "Since most studies ignore transposon RNAs, we want to bring back the attention to these more challenging transcripts to understand how our brains express and metabolize and handle these RNAs during aging."
The implications ripple outward: if transposon RNA processing is a normal part of brain aging, and if that process misfires in disease, then understanding and potentially targeting this mechanism could open new avenues for treatment. It's a reminder that the human genome still holds secrets, and sometimes the most important discoveries come from paying attention to the parts of ourselves we've overlooked.